New Netflix Show to Watch in December 2018: What’s on the Streaming Service This monthAramide Tinubu More Articles The Kardashians are some of the most divided people in the history of American popular culture. Particularly the Kardashian West clan is actually only growing bigger. It was announced in January 2019 that Keeping Up with the Kardashian star Kim Kardashian and her rapper husband Kanye West are expecting their fourth child by surrogate. The baby will join their oldest daughter North son Saint and Chicago infant daughter who was also born in 2017 by surrogate. Although we love babies and are always happy to see their beautiful faces — we wondered why Kardashian wanted to use her fourth baby’s surrogate again. View this post on Instagram Celebrating Saint with a Tarzan-themed party A post shared by Kim Kardashian West (@kimkardashian) on Dec. 11, 2018 at 10:19am PST Carrying a child to full term and then giving birth is far more risky than one would imagine. Although she was able to carry and deliver her first two children to North and Saint, Kim Kardashian suffers from a debilitating and life-threatening condition called placenta accreta. It occurs when the placenta gets too tightly stuck to the uterine wall. Kardashian on her blog recalled how hard it had been to give birth to North. He recalled that My doctor had to put his entire arm in me and remove the placenta with his hand scratching it with his fingernails away from my uterus. How disgusting and distressing!!! My mother wept; she had never seen anything like that before. My delivery was pretty quick but then “it was the most traumatic experience of my life! They gave me a second epidural but we raced against time and I just had to deal with it. They claim some women died from this without proper care as a result of childbirth back in the day. I am so happy that my doctor was able to catch this up and immediately address the issue. Kardashian’s doctor later advised her that carrying a baby and giving birth again would be life threatening for her. She also had Placenta accreta pre-eclampsia which was not the only thing Kardashian had to deal with during her pregnancies. She had also had pre-eclampsia. According to BabyCenter UK, it “causes a decrease in blood flow through the placenta and can mean that the baby won t get enough oxygen and nutrients that may hinder [ their ] development.” Kardashian also became incredibly bloated and uncomfortable. She personally had to deliver six weeks early on to North to prevent any further complications. May the Best Brand ?

Dan RitterGoogle+Twitter More Posts May 31 2013 Fresh! Discover a new stock idea for less than 1 trade.CLICK HERE each week for your Weekly Stock Cheat sheets NOW! As a corporate strategy strategist one quadrant of Shively’s brain was definitely engaged with brand strategy at any given moment. In 2012, Interbrand ranked Microsoft at $57.85 billion as the world’s fifth most valuable brand. Leveraging brand value is a key part of any winning strategy particularly in a market flooded with like-caliber competing products. This is particularly relevant to Shively’s current business venture “the medical and recreational marijuana industry which will expand as high as $500 billion worldwide as he estimates. It’s a huge market in search of a brand Shively said ambitiously adding that if we get 40 per cent of it worldwide, we’d be happy. The exact scale and growth rate of the “medical recreational or both” marijuana industry is hard to determine. A 2005 study from the United Nations pegged the global trade in marijuana to $142 billion. This is a carrot on a stick of course. At it stands there’s no very clear way to estimate the market’s potential size, but it seems safe to say it’s going to be big enough to merit investors’ serious attention. And the game to play for stakeholders is: who can predict which firm will be a winner when the market opens? Shively claims that it is the firm that has the best name. In the U.S. Nima Samadi, a senior analyst at IBISWorld, said the medical marijuana industry has risen to about $1.7 billion in 2013 at a rate of 13.8 per cent per annum over the past five years. We’re going to see much faster growth in the next five years. It’s expected to grow 24.3 percent annually and reach $5 billion [ by 2018 ]. Most of that increase in sales has come from the collectives of non-profit medical marijuana. “It’s light but Samadi hits on an issue here that is critically important to the marijuana industry. There’s plenty of chatter suggesting small and homegrown brands will be the most popular. The power and importance of brand loyalty will arise from the existing social networks and customer relations within the industry as it now exists. The other side of the equation is that there would be a high barrier for outsiders to join the sector. This is one way to address why Shively’s Diego Pellicer business doesn’t seem to be really concerned about an entry into the market of a brand like Marlboro owned by Philip Morris International (NYSE: PM). Philip Morris definitely has the financial resources and the potential to enter the industry, but that is precisely how it is supposed to be viewed by existing market participants “including customers”: an invasion. AND NEW! Discover a new stock idea for less than 1 trade. CLICK HERE each week for your Weekly Stock Cheat sheets NOW! Overall, the area of viable investment candidates can be divided into two categories: relatively new and relatively small industry-specific enterprises and larger, more well-capitalized enterprises that could easily connect to the marijuana industry in case of realistic legalization. The second group comprises big tobacco and big pharma while the first group was gathered into an uncomfortable pool of feasible companies with tradable equity: Business

Market Cap *

Twelve-month revenue trailing * TTM Price-to-sales ratio *

Growlife Inc. (OTC: PHOT)Dan RitterGoogle+Twitter More Posts May 31 2013 Fresh! Discover a new stock idea for less than 1 trade.CLICK HERE each week for your Weekly Stock Cheat sheets NOW! As a corporate strategy strategist one quadrant of Shively’s brain was definitely engaged with brand strategy at any given moment. In 2012, Interbrand ranked Microsoft at $57.85 billion as the world’s fifth most valuable brand. Leveraging brand value is a key part of any winning strategy particularly in a market flooded with like-caliber competing products. This is particularly relevant to Shively’s current business venture “the medical and recreational marijuana industry which will expand as high as $500 billion worldwide as he estimates. It’s a huge market in search of a brand Shively said ambitiously adding that if we get 40 per cent of it worldwide, we’d be happy. The exact scale and growth rate of the “medical recreational or both” marijuana industry is hard to determine. A 2005 study from the United Nations pegged the global trade in marijuana to $142 billion. This is a carrot on a stick of course. At it stands there’s no very clear way to estimate the market’s potential size, but it seems safe to say it’s going to be big enough to merit investors’ serious attention. And the game to play for stakeholders is: who can predict which firm will be a winner when the market opens? Shively claims that it is the firm that has the best name. In the U.S. Nima Samadi, a senior analyst at IBISWorld, said the medical marijuana industry has risen to about $1.7 billion in 2013 at a rate of 13.8 per cent per annum over the past five years. We’re going to see much faster growth in the next five years. It’s expected to grow 24.3 percent annually and reach $5 billion [ by 2018 ]. Most of that increase in sales has come from the collectives of non-profit medical marijuana. “It’s light but Samadi hits on an issue here that is critically important to the marijuana industry. There’s plenty of chatter suggesting small and homegrown brands will be the most popular. The power and importance of brand loyalty will arise from the existing social networks and customer relations within the industry as
it now exists. The other side of the equation is that there would be a high barrier for outsiders to join the sector. This is one way to address why Shively’s Diego Pellicer business doesn’t seem to be really concerned about an entry into the market of a brand like Marlboro owned by Philip Morris International (NYSE: PM). Philip Morris definitely has the financial resources and the potential to enter the industry, but that is precisely how it is supposed to be viewed by existing market participants “including customers”: an invasion. AND NEW! Discover a new stock idea for less than 1 trade. CLICK HERE each week for your Weekly Stock Cheat sheets NOW! Overall, the area of viable investment candidates can be divided into two categories: relatively new and relatively small industry-specific enterprises and larger, more well-capitalized enterprises that could easily connect to the marijuana industry in case of realistic legalization. The second group comprises big tobacco and big pharma while the first group was gathered into an uncomfortable pool of feasible companies with tradable equity: Business

Market Cap *

Twelve-month revenue trailing * TTM Price-to-sales ratio *

Growlife Inc. (OTC: PHOT)

Terra Tech Corp. (TRTC.OB)

$8.69 million $406.81 million

19.64

Hemp Inc. (HEMP.PK)

$26.58 million

$28.14 thousand 958.64

Cannabis Science Inc. (CBIS.OB) $27.44 million

$36.58 thousand

Author

Comments are closed.